A Phase 1, Open-Label Study Evaluating the Pharmacokinetics of N91115 in Cystic Fibrosis Patients
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
Price : $35 *
At a glance
- Drugs Cavosonstat (Primary)
- Indications Cystic fibrosis
- Focus Pharmacokinetics
- Acronyms SNO3
- Sponsors Alpine Immune Sciences; Nivalis Therapeutics
- 25 Jul 2017 According to a Alpine Immune Sciences media release, Alpine Immune Sciences acquired Nivalis Therapeutics and the combined companies changed its name to Alpine Immune Sciences.
- 12 Aug 2016 Status changed from active, no longer recruiting to completed.
- 04 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Feb 2016, as reported by ClinicalTrials.gov record.